2 / 7
Page 52
Notes:
allied
academies
J Med Oncl Ther 2017 Volume 2 | Issue 3
International Conference on
Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Predictive value of PKM2 expression in advanced non-small cell lung cancer patients (NSCLC) treated
with front-line platinum-based chemotherapy
Mohamed Sheta, Omnia Abd –El-Fattah
and
Hanan A Alshenawy
Tanta University Hospital, Egypt
T
he aim of the study is to assess the expression of PKM2
in advanced NSCLC patients treated with front-line
platinum-based chemotherapy and analyze its predictive
value on both progression free and overall survival and
72 cases with histologically confirmed stage IIIB and IV
NSCLC who were treated with front-line platinum-based
chemotherapy. Thirty two NSCLC patients were treated with
front-line non-platinum-based doublets were enrolled in this
study (as control), Immunohistochemical staining for PKM2
was evaluated. in Platinum group the median OS was 7 vs.
19 months; P˂0.001 for those patients with high compared
to those with low PKM2 expression respectively and the
median PFS was 5 vs. 9 months; P˂ 0.001 for those patient
with high compared to those with low PKM2 expression
respectively. In control group there was no significant
difference between high and low PKM2 expression as regard
median OS (9 vs. 10 months; P =˂0.451) and median PFS (7
vs. 8 months; P= 0.638). The multivariate analysis revealed
that high PKM2 expression was an independent predictive
factor for shorter PFS and decreased OS. Our study proved
that PKM2 expression may be a predictive biomarker of
platinum sensitivity in advanced NSCLC patients treated with
platinum-based chemotherapy.
Speaker Biography
Mohamed Sheta is a Lecturer of Clinical Oncology and Nuclear Medicine and Consultant
of Clinical Oncology at Nile Hospital for Medical Insurance, Cairo in, Tanta University.
He has published his papers in reputed journals.
e:
Mohamed_sheta1@yahoo.com